OncologyDr. Niti RaizadaCommon Cancers & Blood Disorders

Principal Director, Medical Oncology & Hemato-Oncology, Fortis Hospital, Bannerghatta Road, Bengaluru, India

Part 8 of 12 in Diagnosing Common Cancers & Blood Disorders

HPV Vaccination: Who Needs It and What It Prevents

August 28, 2026

Human papillomavirus does more damage than its name suggests to most patients. Beyond cervical cancer, HPV causes vaginal and vulval cancer in women, penile cancer in men, anal cancer in both sexes, and a subset of head and neck cancers, including oropharyngeal cancer. Dr. Niti Raizada devoted a significant part of her masterclass to making sure every clinician on the call knew exactly who should be vaccinated and when, because unlike most of the cancers discussed in this series, HPV-related cancer is genuinely preventable at the point of infection.

The WHO dosing schedule, by age

Vaccination is recommended for all children, both girls and boys, starting at age 9 through age 14. Per World Health Organization guidance, this age group receives two doses, given six months apart. From age 15 through 45, the recommended schedule shifts to three doses, given at 0, 2 and 6 months.

Bivalent, quadrivalent, and nine-valent: what the difference means in practice

Several vaccine formulations are in use. The nine-valent, or nonavalent, vaccine covers the widest range of HPV strains but is also the most expensive. The quadrivalent vaccine is the most commonly used formulation and is effective. In India, an indigenously developed HPV vaccine has become available, which has meaningfully brought down the cost of vaccination. The two most important cancer-causing, or oncogenic, strains are HPV 16 and 18, and even the bivalent vaccine, the simplest formulation, protects against both.

Can a patient already infected with HPV still be vaccinated?

This question came up directly during the masterclass, and Dr. Raizada's answer was unambiguous: yes. If a patient tests positive for one strain of HPV and receives a nine-valent vaccine, the vaccine still confers protection against the remaining eight strains it covers. A positive HPV test is not a reason to withhold vaccination.

Vaccination does not replace screening

Dr. Raizada was equally direct on this point: even after a patient has been vaccinated, cervical cancer screening must continue on the same schedule as for anyone else. Vaccination reduces the risk of the strains it covers; it does not eliminate the need for Pap smear and HPV co-testing at the intervals described in the previous article in this series.

The clinical takeaway

For any clinician advising a family on HPV vaccination, the schedule is straightforward to remember: two doses between 9 and 14, three doses between 15 and 45, and screening continues regardless. Given how many cancer sites HPV touches beyond the cervix, Dr. Raizada's view is that every eligible patient, not only girls, should be offered the vaccine as a routine part of preventive care.

This guide is based on a live Jivo Masterclass — Dr. Niti Raizada taught doctors across Africa on February 1, 2026.

FROM THE LIVE Q&A

DR

Dr. Ivan

Could you recap the management of leukemia, including the case you discussed earlier?

NR

Dr. Niti Raizada

Leukemias are broadly acute or chronic. Acute leukemias have a short history with low hemoglobin, white cell count and platelets, presenting with fever and bleeding. Chronic leukemias, chronic myeloid leukemia (CML) or chronic lymphocytic leukemia (CLL), generally occur in older age groups and are often managed with tablets alone. Acute leukemias are either AML or ALL. Genetic testing subcategorises each: CML needs confirmation of Philadelphia chromosome or BCR-ABL positivity; CLL needs a FISH panel to check p53 status and risk category; AML is categorised as good, intermediate or high risk. ALL is the most common leukemia in children and young adults and is treated with steroids followed by chemotherapy based on T-cell or B-cell type. AML M3, acute promyelocytic leukemia, is rare but very curable with ATRA or arsenic trioxide tablets; non-M3 AML needs chemotherapy.

See all 9 questions from this masterclass →

Book a Consultation with Dr. Niti Raizada

Book on WhatsApp

Or message us on WhatsApp: +91 98182 98669

Frequently Asked Questions

What comfort or guidance can you give the doctor partners here, who may not always have clarity because of diagnostic challenges? When should a case trigger further action?

Please write in with any questions, over WhatsApp or text, at any time. Many patients cannot travel to India, so the goal is to help diagnose and treat them on time wherever they are. Prepare a doctor's note with the relevant clinical details and share it; if the picture is clear, specific pointers on managing the case can be given from that.

Can a general practitioner also perform a clinical breast examination, or does it need to be a specialist?

Self-examination should be done by the woman herself, using the opposite hand on the opposite breast with three fingers held flat, including the axilla and neck. Clinical breast examination should be done by anyone properly trained, which can include nurse practitioners, physician assistants, internal medicine doctors, general surgeons, gynaecologists and oncologists. Training, not job title, is what matters, since missing lesions is common when the examiner has not been trained. GPs and internal medicine doctors should learn the technique and offer it to every woman who comes to the clinic.

What further investigations are needed to assess disease extension before starting management of this cervical cancer case?

Once the diagnosis is confirmed by biopsy, a staging scan, often a PET scan, establishes the exact stage, including whether the bladder, rectum, parametrium or lymph nodes are involved. Fitness for treatment is then assessed with kidney function testing (GFR) and audiometry, since some chemotherapy agents can affect hearing. Weekly chemotherapy is then given alongside radiation, with the potential radiation side effects explained to the patient beforehand.

Between MRI and CT scan, which is the better imaging modality for staging this cervical cancer case?

MRI of the pelvis is excellent for local pelvic structures, but the upper abdomen and chest still need to be assessed, which is better done on CT. The recommendation is CT of the thorax combined with CT of the abdomen and pelvis with contrast, or alternatively MRI of the abdomen and pelvis with contrast combined with a CT of the chest. The chest is generally better seen on CT, and the pelvis is generally better seen on MRI.

I am seeing a Stage III breast cancer patient currently on filgrastim 300 micrograms for 3 days. What further treatment plan would you initiate for this patient?

Treatment depends on the patient's oestrogen receptor, progesterone receptor and HER2 status, and on whether she is receiving neoadjuvant chemotherapy followed by surgery, or surgery followed by adjuvant chemotherapy. Filgrastim is supportive care only, a white blood cell growth factor given to prevent a drop in counts after chemotherapy; it is not the primary cancer treatment. Its use depends on which chemotherapy protocol is being followed, but the treatment plan for the cancer itself is a separate, biology-driven decision.

At what ages is the HPV vaccine recommended, and how many doses are needed?

Children of both sexes from age 9 to 14 receive two doses given six months apart. From age 15 to 45, the schedule shifts to three doses given at 0, 2, and 6 months.

What is the difference between bivalent, quadrivalent, and nine-valent HPV vaccines?

The nine-valent, or nonavalent, vaccine covers the widest range of HPV strains but costs the most. The quadrivalent vaccine is the most commonly used and effective formulation. The bivalent vaccine, the simplest option, still protects against HPV 16 and 18, the two most important cancer-causing strains.

Does HPV vaccination eliminate the need for cervical cancer screening?

No. Vaccination reduces the risk from the strains it covers, but cervical cancer screening must continue on the same schedule as for any other patient.

How has India's indigenous HPV vaccine changed access to vaccination?

An indigenously developed HPV vaccine in India has meaningfully lowered the cost of vaccination, making it more accessible without changing the recommended dosing schedule.

Need Expert Medical Guidance?

Connect with leading specialists through the Jivo Healthcare network for personalized advice.

Get Expert Opinion